Overview

Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer

Status:
WITHDRAWN

Trial end date:
2028-02-28

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter, interventional study in racially self-identified black or ethnically self-identified hispanic and racially self-identified white or native American participants with metastatic castration-resistant prostate cancer whose tumors demonstrate molecular alterations compatible with homologous repair deficiency.

Phase:

PHASE2

Details

Lead Sponsor:

Latin American Cooperative Oncology Group

Collaborator:

Janssen, LP

Treatments:

niraparib
Prednisone